Illumina, Inc. DEF 14A Filing

Ticker: ILMN · Form: DEF 14A · Filed: Apr 4, 2024 · CIK: 1110803

Illumina, INC. DEF 14A Filing Summary
FieldDetail
CompanyIllumina, INC. (ILMN)
Form TypeDEF 14A
Filed DateApr 4, 2024
Risk Levelmedium
Pages14
Reading Time17 min
Key Dollar Amounts$1 million
Sentimentneutral

Sentiment: neutral

Topics: DEF 14A, Illumina, Executive Compensation, Shareholder Meeting, Corporate Governance

TL;DR

<b>Illumina, Inc. filed its DEF 14A proxy statement on April 4, 2024, detailing executive compensation and corporate governance matters.</b>

AI Summary

ILLUMINA, INC. (ILMN) filed a Proxy Statement (DEF 14A) with the SEC on April 4, 2024. Illumina, Inc. filed a DEF 14A form on April 4, 2024. The filing covers the period ending May 16, 2024. The company's principal executive offices are located at 5200 Illumina Way, San Diego, CA 92122. The filing includes detailed information on executive compensation and equity awards. Key individuals mentioned include Francis DeSouza, Charles Dadswell, and Jacob Thaysen.

Why It Matters

For investors and stakeholders tracking ILLUMINA, INC., this filing contains several important signals. This filing is crucial for shareholders to understand executive compensation structures and make informed voting decisions at the upcoming annual meeting. The DEF 14A provides transparency into how the company values and awards equity to its top executives, which can impact shareholder value and corporate strategy.

Risk Assessment

Risk Level: medium — ILLUMINA, INC. shows moderate risk based on this filing. The filing is a DEF 14A, which is a routine disclosure for public companies regarding executive compensation and shareholder matters, indicating a standard level of corporate activity rather than significant positive or negative events.

Analyst Insight

Review the executive compensation details and any proposed shareholder resolutions to inform voting decisions.

Key Numbers

Key Players & Entities

FAQ

When did ILLUMINA, INC. file this DEF 14A?

ILLUMINA, INC. filed this Proxy Statement (DEF 14A) with the SEC on April 4, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by ILLUMINA, INC. (ILMN).

Where can I read the original DEF 14A filing from ILLUMINA, INC.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by ILLUMINA, INC..

What are the key takeaways from ILLUMINA, INC.'s DEF 14A?

ILLUMINA, INC. filed this DEF 14A on April 4, 2024. Key takeaways: Illumina, Inc. filed a DEF 14A form on April 4, 2024.. The filing covers the period ending May 16, 2024.. The company's principal executive offices are located at 5200 Illumina Way, San Diego, CA 92122..

Is ILLUMINA, INC. a risky investment based on this filing?

Based on this DEF 14A, ILLUMINA, INC. presents a moderate-risk profile. The filing is a DEF 14A, which is a routine disclosure for public companies regarding executive compensation and shareholder matters, indicating a standard level of corporate activity rather than significant positive or negative events.

What should investors do after reading ILLUMINA, INC.'s DEF 14A?

Review the executive compensation details and any proposed shareholder resolutions to inform voting decisions. The overall sentiment from this filing is neutral.

How does ILLUMINA, INC. compare to its industry peers?

Illumina operates in the biotechnology and life sciences industry, focusing on genomic sequencing and array technologies.

Are there regulatory concerns for ILLUMINA, INC.?

DEF 14A filings are regulated by the SEC and require detailed disclosure of corporate governance, executive compensation, and matters to be voted on by shareholders.

Industry Context

Illumina operates in the biotechnology and life sciences industry, focusing on genomic sequencing and array technologies.

Regulatory Implications

DEF 14A filings are regulated by the SEC and require detailed disclosure of corporate governance, executive compensation, and matters to be voted on by shareholders.

What Investors Should Do

  1. Review the proxy statement for details on executive compensation and any proposed shareholder actions.
  2. Assess the company's governance practices as outlined in the filing.
  3. Note the filing date and period of report for tracking purposes.

Year-Over-Year Comparison

This is a DEF 14A filing, which is a standard disclosure document for annual shareholder meetings and does not represent a change from previous filings of the same type.

Filing Stats: 4,332 words · 17 min read · ~14 pages · Grade level 13.2 · Accepted 2024-04-04 16:17:19

Key Financial Figures

Filing Documents

Executive Compensation

Executive Compensation 67 Proposal 3: Advisory Vote on Compensation 77 Our Leadership 78

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 79 Users' Guide 81 Annex A – Reconciliation of Non-GAAP Measures 92 Table of Contents Who We Are Our Mission To improve human health by unlocking the power of the genome. Our Company We are a global leader in sequencing- and array-based solutions for genetic and genomic analysis. Our products and services serve customers in a wide range of markets, enabling the adoption of genomic solutions in research and clinical settings. Researchers and clinicians use our products to analyze the genome at all levels of complexity, from targeted panels to whole-genome sequencing. This enables them to discover, detect, diagnose, and treat diseases from cancer to COVID-19. Our Markets Illumina is innovating across multiple markets which include: Research & Applied Markets: Historically our core business has been in the life sciences research market, which includes laboratories associated with universities, research centers, and government institutions, along with biotechnology and pharmaceutical companies. Clinical Markets: We have increased our focus on enabling translational and clinical markets through the introduction of best-in-class sequencing technology, including in reproductive and genetic health and oncology. By assessing many genes simultaneously, our next-generation sequencing (NGS) technology is also accelerating rare and undiagnosed disease research to discover the genetic causes of inherited disorders. Using NGS can reduce costs compared to traditional methods of disease diagnosis, which are often expensive and inconclusive while requiring extensive testing. Key Focus Areas Research & Applied Cancer Microbiology Agrigenomics Complex Disease Cell & Molecular Biology Clinical Reproductive Health Genetic & Rare Disease Oncology Illumina, Inc. 2024 Proxy Statement1 Table of Contents Skilled Director Nominees & Robust Corporate Governance The Board of

: Gender Identity

Part I: Gender Identity Directors 3 8 0 0

: Demographic Background

Part II: Demographic Background African American or Black 0 0 0 0 Alaskan Native or Native American 0 0 0 0 Asian 1 0 0 0 Hispanic or Latinx 0 0 0 0 Native Hawaiian or Pacific Islander 0 0 0 0 White 2 8 0 0 Two or More Races or Ethnicities 0 0 0 0 LGBTQ+ 0 Did Not Disclose Demographic Background 0 Illumina, Inc. 2024 Proxy Statement5 Table of Contents 2024 Director Nominees Upon the recommendation of the Nominating/Corporate Governance Committee of the Board, the Board of Directors has nominated for election at the 2024 annual meeting the eleven nominees named in the table below to hold office until the annual meeting of stockholders in 2025 and until their successors are duly elected and qualified or until their earlier death, resignation, retirement, disqualification or removal from office. The Nominating/Corporate Governance Committee has recommended that Ms. Anna Richo be elected as a new director at the 2024 annual meeting. In today's evolving global business and regulatory environment, the Committee determined that the addition of Ms. Richo will broaden the skills of the current Board, particularly given her legal, compliance and ethics expertise. Mr. Andrew Teno will not be standing for re-election at the 2024 annual meeting of stockholders. Name Age Independent Director Since Principal Occupation Frances Arnold, Ph.D. 67 2016 Linus Pauling Prof. of Chemical Engineering, Biochemistry & Bioengineering at the California Institute of Technology; Director at Alphabet Caroline D. Dorsa 64 2017 Board Chair at Biogen Robert S. Epstein, M.D. 68 2012 CEO & Co-founder of Epstein Health LLC; Board chair at Veracyte Scott Gottlieb, M.D. 51 2020 Partner at New Enterprise Associates and senior fellow at AEI; Former FDA Commissioner; Director at Pfizer Gary S. Guthart, Ph.D. 58 2017 President and CEO at Intuitive Surgical Stephen P. MacMillan, Chair 6

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing